U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
116683
Substance Class Protein
Created
by admin
on Sat Jun 26 18:06:57 UTC 2021
Edited
by admin
on Sat Jun 26 18:06:57 UTC 2021
Protein Sub Type
Sequence Type COMPLETE
Record UNII
6NP3XSMIP3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
Common Name English
MATE1
Common Name English
FLJ10847
Common Name English
SOLUTE CARRIER FAMILY 47 MEMBER 1
Common Name English
SLC47A1
Common Name English
MGC64822
Common Name English
MATE-1
Common Name English
Classification Tree Code System Code
UCSF-FDA TRANSPORTAL SLC47A1
Created by admin on Sat Jun 26 18:07:04 UTC 2021 , Edited by admin on Sat Jun 26 18:07:04 UTC 2021
Code System Code Type Description
FDA UNII
6NP3XSMIP3
Created by admin on Sat Jun 26 18:07:04 UTC 2021 , Edited by admin on Sat Jun 26 18:07:04 UTC 2021
PRIMARY
Related Record Type Details
Structure of METHAMPHETAMINE
INHIBITOR -> TRANSPORTER
IC50
Structure of ACYCLOVIR
SUBSTRATE -> TRANSPORTER
Structure of RIFAMYCIN
INHIBITOR -> TRANSPORTER
Rifamycin is an inhibitor of renal transporters organic anion transporter (OAT) 3, multidrug and toxin extrusion (MATE) 1, and MATE2-K transporters in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose, clinically relevant inhibition of these transporters in vivo is unlikely.
Structure of AMANTADINE
INHIBITOR -> TRANSPORTER
Structure of DM-3411
TRANSPORTER -> INHIBITOR
Structure of ESTRONE SULFATE
SUBSTRATE -> TRANSPORTER
Structure of FAMOTIDINE
INHIBITOR -> TRANSPORTER
Structure of SIROLIMUS
INHIBITOR -> TRANSPORTER
Structure of DILTIAZEM
INHIBITOR -> TRANSPORTER
Structure of CEPHALEXIN
SUBSTRATE -> TRANSPORTER
Structure of IMEGLIMIN
INHIBITOR -> TRANSPORTER
Structure of CABOZANTINIB
INHIBITOR -> TRANSPORTER
IC50
Structure of N-BUTYLPYRIDINIUM CHLORIDE
INHIBITOR -> TRANSPORTER
Structure of TOPOTECAN
SUBSTRATE -> TRANSPORTER
Structure of PROCAINAMIDE
SUBSTRATE -> TRANSPORTER
Structure of TETRAETHYLAMMONIUM
SUBSTRATE -> TRANSPORTER
Structure of REMDESIVIR
INHIBITOR -> TRANSPORTER
Structure of OLAPARIB
INHIBITOR -> TRANSPORTER
INHIBITOR
IC50
Structure of RANITIDINE
INHIBITOR -> TRANSPORTER
ERVOGASTAT
INHIBITOR -> TRANSPORTER
Structure of AMISULPRIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of 1-(((4-((7-METHOXY-6-(SULFOOXY)-4-QUINOLINYL)OXY)PHENYL)AMINO)CARBONYL)CYCLOPROPANECARBOXYLIC ACID
INHIBITOR -> TRANSPORTER
IC50
Structure of DISOPYRAMIDE
INHIBITOR -> TRANSPORTER
Structure of TALIPEXOLE
INHIBITOR -> TRANSPORTER
CEPHRADINE
SUBSTRATE -> TRANSPORTER
Structure of RIBOCICLIB
INHIBITOR -> METABOLIC ENZYME
Structure of COBICISTAT
INHIBITOR -> TRANSPORTER
Structure of LEVOFLOXACIN ANHYDROUS
INHIBITOR -> TRANSPORTER
Structure of VERAPAMIL
INHIBITOR -> TRANSPORTER
Structure of AMPHETAMINE
SUBSTRATE -> TRANSPORTER
Structure of RISDIPLAM
INHIBITOR -> TRANSPORTER
IN VITRO
Structure of CHLORPHENIRAMINE
INHIBITOR -> TRANSPORTER
Structure of QUINIDINE
INHIBITOR -> TRANSPORTER
Structure of PRALSETINIB
INHIBITOR -> TRANSPORTER
Structure of PLAZOMICIN
INHIBITOR -> TRANSPORTER
Structure of DESIPRAMINE
INHIBITOR -> TRANSPORTER
Structure of RUCAPARIB
INHIBITOR -> TRANSPORTER
Structure of METFORMIN
INHIBITOR -> TRANSPORTER
Structure of PROCAINAMIDE
INHIBITOR -> TRANSPORTER
Structure of CETIRIZINE HYDROCHLORIDE
INHIBITOR -> TRANSPORTER
Structure of IMIPRAMINE
INHIBITOR -> TRANSPORTER
Structure of CAPMATINIB
INHIBITOR -> TRANSPORTER
REVERSIBLE
Structure of MITOXANTRONE
INHIBITOR -> TRANSPORTER
Structure of CHLOROQUINE
INHIBITOR -> TRANSPORTER
Structure of GANCICLOVIR
SUBSTRATE -> TRANSPORTER
Structure of AMISULPRIDE
INHIBITOR -> TRANSPORTER
HUMAN LIVER
TISSUE EXPRESSION->TRANSPORTER
Structure of SOLRIAMFETOL
INHIBITOR -> TRANSPORTER
WEAK
IC50
Structure of BRANEBRUTINIB
INHIBITOR -> TRANSPORTER
Structure of CYPERQUAT
SUBSTRATE -> TRANSPORTER
Structure of SELPERCATINIB
INHIBITOR -> TRANSPORTER
Structure of DX-619
INHIBITOR -> TRANSPORTER
Structure of CIMETIDINE
SUBSTRATE -> TRANSPORTER
Structure of TIRBANIBULIN
INHIBITOR -> TRANSPORTER
The results suggest that KLISYRI has no clinically meaningful effect on the PK of drugs mediated by MATE1
IC50
Structure of FEDRATINIB
INHIBITOR -> TRANSPORTER
IC50
Structure of CIMETIDINE
INHIBITOR -> TRANSPORTER
Structure of APALUTAMIDE
INHIBITOR -> TRANSPORTER
Structure of TAFENOQUINE
INHIBITOR -> TRANSPORTER
IC50
Structure of GUANIDINE
SUBSTRATE -> TRANSPORTER
Structure of IMEGLIMIN
SUBSTRATE -> TRANSPORTER
Structure of METFORMIN
SUBSTRATE -> TRANSPORTER
Structure of LORLATINIB
INHIBITOR -> TRANSPORTER
Structure of PROCAINAMIDE
SUBSTRATE -> TRANSPORTER
Structure of BICTEGRAVIR
INHIBITOR -> TRANSPORTER
Co?administration of BIKTARVY with dofetilide may increase dofetilide plasma concentrations which can lead to serious and/or life threatening events.
CLINICALLY SIGNIFICANT
IC50
Structure of CIPROFLOXACIN
INHIBITOR -> TRANSPORTER
Structure of GILTERITINIB
INHIBITOR -> TRANSPORTER
IC50
Structure of DIPHENHYDRAMINE
INHIBITOR -> TRANSPORTER
Structure of METHAMPHETAMINE
SUBSTRATE -> TRANSPORTER
Structure of PRAMIPEXOLE
INHIBITOR -> TRANSPORTER
Structure of GLASDEGIB
INHIBITOR -> TRANSPORTER
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966